5/10/2026

Janusmed sex and gender

Janusmed sex and gender – aripiprazole

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Aripiprazole

Aripiprazole

Class : C

Show all info

Print

Contact us

  1. Food and Drug Administration (FDA). Abilify (aripiprazole) drug label. Drugs@FDA [www]. [updated 2002-11-15, cited 2026-03-31].

  2. Hoekstra S, Bartz-Johannessen C, Sinkeviciute I, Reitan SK, Kroken RA, Løberg EM et al. Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophr. 2021;7(1):39.

  3. Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.

  4. Abilify (aripiprazole). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2026-01-12, 2026-03-31]

  5. Stephen Marder, MD and T Scott Stroup, MD, MPH. Pharmacotherapy for schizophrenia: Side effect management. UpToDate [www]. [updated 2019-10-16, cited 2020-06-30].

  6. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Garcia-Unzueta MT, Labad J, Correll C, Ayesa-Arriola R. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophr Res. 2017;189:134-141.

  7. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214-220.

  8. Öztürk Yalçın Z, Bayraktar İ, Kaşıkcı M, Yalçın N, Özçelik Eroğlu E, Yağcıoğlu AEA et al. Beyond dose: Antipsychotic risk categories and sex-specific vulnerability to hyperprolactinemia in real-world longitudinal care. Psychoneuroendocrinology. 2026;188:107838.

  9. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.

  10. Qi F, Tian L, Diao H, Zhao S, Li F, Zhang Y et al. Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: A pharmacovigilance study based on the FAERS database. J Affect Disord. 2025;388:119435.

  11. Stamoula E, Stamatellos VP, Vavilis T, Dardalas I, Papazisis G. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS). Expert Opin Drug Saf. 2024;23(2):239-245.

  12. McCall KL, Leppien EE, Piper BJ, Falco BM, Fleck KK, Govel JC et al. Second-Generation Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database. J Clin Psychopharmacol. 2025;45(2):111-115.

  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Food and Drug Administration (FDA). Abilify (aripiprazole) drug label. Drugs@FDA [www]. [updated 2002-11-15, cited 2026-03-31].
  2. Hoekstra S, Bartz-Johannessen C, Sinkeviciute I, Reitan SK, Kroken RA, Løberg EM et al. Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophr. 2021;7(1):39.
  3. Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.
  4. Abilify (aripiprazole). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2026-01-12, 2026-03-31]
  5. Stephen Marder, MD and T Scott Stroup, MD, MPH. Pharmacotherapy for schizophrenia: Side effect management. UpToDate [www]. [updated 2019-10-16, cited 2020-06-30].
  6. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Garcia-Unzueta MT, Labad J, Correll C, Ayesa-Arriola R. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophr Res. 2017;189:134-141.
  7. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214-220.
  8. Öztürk Yalçın Z, Bayraktar İ, Kaşıkcı M, Yalçın N, Özçelik Eroğlu E, Yağcıoğlu AEA et al. Beyond dose: Antipsychotic risk categories and sex-specific vulnerability to hyperprolactinemia in real-world longitudinal care. Psychoneuroendocrinology. 2026;188:107838.
  9. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.
  10. Qi F, Tian L, Diao H, Zhao S, Li F, Zhang Y et al. Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: A pharmacovigilance study based on the FAERS database. J Affect Disord. 2025;388:119435.
  11. Stamoula E, Stamatellos VP, Vavilis T, Dardalas I, Papazisis G. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS). Expert Opin Drug Saf. 2024;23(2):239-245.
  12. McCall KL, Leppien EE, Piper BJ, Falco BM, Fleck KK, Govel JC et al. Second-Generation Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database. J Clin Psychopharmacol. 2025;45(2):111-115.
  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]